Multiple articles focus on new results from non-alcoholic fatty liver research!

In this paper, the small compilation of a number of research results, together focus on scientists in the field of non-alcoholic fatty liver research achievements! Share it with everyone! Photo Credit: karaacevedo013.wikidot.com:Sci Transl Med: Uncovering new molecular pathways promises to help develop new treatments for non-alcoholic fatty liver: 10.1126/scitranslmed.aaw9709 In a study published in the international journal Science Translational Medicine, scientists from institutions such as the Caroline Institute in Sweden have found a special molecular pathway that, when silent, restores normal function of immune cells in patients with fatty liver, offers new ideas and hopes for developing new treatments for diseases such as fatty liverFatty liver is a major health risk factor for obesity in the population; non-alcoholic fatty liver disease (NAFLD) is a disease that accumulates too much fat in the liver of people with low or no alcohol intake, and is also common in people with diabetes and obesity, and there is currently no effective treatment for NAFLDFor the study, the researchers wanted to analyze what happens to fat in the liver of humans and mice when it is overloaded at the cellular and molecular levels, and how to recover the damageThey found that white blood cells, liver macrophages, which are important to the immune system, can react to unnecessary fat by trying to burn fat, in which they end the excessive production of oxides that promote liver damage, and in further studies found that the antioxidant protein, nRF2, which usually protects the body from harmful oxidative damage, is completely shut down in obese individuals and the body's mouse liverAnn Inter Med: Tumor immunotherapy may cause non-alcoholic fatty liver disease: 10.7326/L19-0635 Non-alcoholic fatty liver disease (NAFLD) patients are mostly overweight and obeseHowever, in patients with rare genetic disorders such as fatty malnutrition or HIV, severe forms of NAFLD can also be detected, making them at high risk for liver failure, diabetes and cardiovascular diseaseNow, norbert Stefan, a researcher from Germany, and colleagues have discovered what causes NAFLD in thin peopleThey reported a case of a woman receiving skin immunoimmune checkpoint therapy that may have triggered subcutaneous fat inflammation in the patient, leading to a significant reduction in fat and severe NAFLDThe worldwide prevalence of NAFLD is believed to be due to unhealthy lifestyles, rare physical activity and diets rich in saturated fat, sugar and fructoseAmong these overweight and obese patients, lifestyle changes to reduce weight loss are considered the most effective and safest way to treat NAFLD and reduce the risk of advanced liver diseasesuch as cirrhosis or liver cancer, type 2 diabetes and cardiovascular disease (CVD)However, patients with leaner body size also develop NAFLD symptoms, accompanied by reduced body fat but increased abdominal fatThree articles are published together! Scientists develop new treatment for non-alcoholic fatty liver! doi: 10.1016/S2468-1253 (19) 30184-0, published in the international journal The Lancet Gastroenterology and Hepatology, from the Medical University of Vienna, Austria Scientists have illustrated the efficacy of synthetic bile acid combination active formulation non-bear deoxychoso in the treatment of primary sclerosing bile ductitis (PSC), a liver disease that has so far been incurableIn a clinical trial, researchers found that nor-urso is also effective in treating non-alcoholic fatty liver disease, which currently affects non-alcoholic fatty liver disease, which is often caused by poor lifestyle, excess body fat and sugar, and lack of exercise, often in parallel with obesityIn the 50-60 year-old population, 35%-50% of the population will develop fatty liver, fatty liver is a silent disease, usually only in the individual occasional physical examination, but long-term fatty liver can seriously affect the health of the body, and lead to cirrhosis and liver cancer, in all fatty liver disease, about 10%-30% will be classified as the most dangerous liver fatty fatty hepatitis/ NASH, which will subsequently lead to 15%-25% of patients with cirrhosisBJP: A new molecule or promising to treat type 2 diabetes and non-alcoholic fatty liver disease: 10.1111/bph.14678 In a recent study published in the international journal British Journal of Journal, scientists from the University of Barcelona and others found that a new molecule called EPB-53 may help fight type 2 diabetes and non-alcoholic fatty liver diseaseFGF21 hormone (fibroblast growth factor 21) is an endocrine factor that plays a decisive role in energy metabolism as an anti-diabetic and anti-obesity agent, and is considered a potential therapeutic target for treating type 2 diabetes and non-alcoholic fatty liver; JMF: Sage Lactobacillus or can balance the gut microbiome and improve chronic alcoholic liver damage doi: 10.1089/jmf.2018.4357 Recently, a study published in the international journal Journal of The Sawith of The Sauerta, from Jilin Agricultural University and other Scientists at the research institute found that Lactobacillus rhamnosus may re-establish the balance of the intestinal microbiome in a dose-dependent manner and effectively combat the damaging effects of alcohol intake on the liver of mice, effectively reversing chronic alcohol-alcohol liver damageFor the study, the researchers gave mice eight weeks of alcohol and fed them two-week-old rat lactobacillis particles (LGG, Lactobacillus rhamnosus granules) and mice indifferent to different doses of LGG (low, medium and high) while on a high-fat diet The researchers found that LGG intake improved alcohol-induced liver damage by reducing liver accumulation and inflammatory reactions in the liver in mice in a dose-dependent manner Photo Credit: Cell: Key proteins help inhibit the occurrence of non-alcoholic fatty liver: 10.1016/j.cell.2019.04.010 Fatty liver is a disease that is not currently treated Non-alcoholic fatty liver disease is associated with several different severity of liver dysfunction, characterized by the accumulation of fat in liver cells and not caused by high drinking The disease is one of the most common in developed countries, affecting about 25 per cent of the world's population Recently, researchers have identified a possible treatment target for fatty liver disease - a team of researchers at the Institute for Biomedical Research has identified a preventable factor for the disease, the protein Mitofusin 2 Mitofusin 2 emerged as a possible therapeutic target for the treatment of fatty liver, an untreatable disease Early diagnosis of the disease is difficult, and doctors are currently only recommending weight loss to ease the condition One of the most serious forms of disease is non-alcoholic fatty hepatitis (NASH), in which fat accumulation is accompanied by inflammation In the study, published in the journal Cell, the researchers observed a decrease in mitofusin levels in PATIENTs with NASH, even in the early stages of the disease J Hepatol: Be careful! Red and processed meats increase the risk of non-alcoholic fatty liver! doi: 10.1016/j.jhep.2018.01.015 A new study has linked non-alcoholic fatty liver (NAFLD) to the heavy consumption of red and processed meat NAFLD is a liver metabolic syndrome whose main pathological characteristics are insulin tolerance and inflammation, and unhealthy Western lifestyles play a key role in the occurrence and progression of NAFLD, i.e lack of exercise, heavy consumption of fructose and saturated fat The study involved cross-analysis of people aged 40-70 All participants underwent enteroscopy at Tel Aviv Medical Center and agreed to participate in the 2013-2015 metabolic and liver disease screening study The study involved 800 participants, and 357 people completed a questionnaire survey on the meat they ate and the common cooking methods they used Unhealthy processing methods include frying or roasting meat, as these processes produce inflammatory compounds called heterocyclic amine (HCAs) 8: Hepatology: Wuhan University scholars have found a potential new target for the treatment of non-alcoholic fatty liver disease doi: 10.1002/hep.29820 intracellular fat over-deposition is a major feature of non-alcoholic fatty liver disease, which is associated with insulin resistance and other related metabolic stress liver injuries With the epidemic trend of globalization of obesity and its associated metabolic syndrome, non-alcoholic fatty liver disease has become an important cause of chronic liver disease in developed countries in Europe and America and parts of China Non-alcoholic fatty liver disease is a new challenge in contemporary medicine, and the harm to human health is increasing Tumor progression locus2 (TPL2) is a serine/tyrosine kinase that has previously been found to be a potential target for a variety of diseases involved in the treatment of inflammatory components However, there is still less understanding of how TLP2 regulates liver cell metabolism and liver inflammation in non-alcoholic fatty liver disease Researchers from Wuhan University recently explored this issue, and the findings were published in the international academic journal Hepatology 9: Chinese scholars found that the control of non-alcoholic fatty liver important moleculedo: 10.1002/hep.2977 adenosine widely distributed in the whole body tissue organs, can be combined with the G protein conjugate receptor on the cell surface to play a role in suppressing the inflammatory response, adenosine receptor has Multiple subtypes, in which adenosine 2A receptor (A2AR) is widely distributed in glial cells, macrophages, dendritic cells, fat cells, natural killer cells and other immune cells and endothelial cells and epithelial cells play a protective role in avoiding tissue damage caused by endotoxins and ischemia But the role of A2AR in non-alcoholic fatty liver disease (NAFLD) is unclear In a new study published in the international academic journal Hepatology, Chinese scholar Chaodong Wu and others from Texas Agricultural University in the United States built mouse models of A2AR systemic knockout and bone marrow cell-specific knockout to study the molecular effects on obesity-related NAFLD and explain the mechanisms in it In the study, researchers fed high-fat mice and control mice a high-fat diet to induce NAFLD, and tested the inflammatory and metabolic responses of bone marrow-derived macrophages and mouse progenitor liver cells They found that after a high-fat diet, whole-body knockout mice and tissue-specific knockout mice showed more severe liver fat immersion and inflammatory changes In vitro experiments showed that macrophages that were missing A2AR showed a stronger inflammatory response, and that their co-cultivation with wild progeny liver cells also promoted fat deposition of liver cells In primary liver cells, the absence of A2AR strengthens the inflammatory response and the promoter of palmic acid on fat deposition The absence of A2AR also significantly increased the expression of the liver of hungry mice and the liver cell translvirus factor SREBP1c, which deprived of nutrients, and after the absence of A2AR, the transcriptional activity of SREBP1c increased significantly in mouse liver cells Hepatol Commun: How does a high-fat diet trigger non-alcoholic fatty liver? Doi: 10.1002/hep4.1041 A recent study led by Rohit Kohli of Children's Hospital los Angeles identified a class of key inflammatory cells involved in non-alcoholic fatty liver disease The main way to address the disease is through changes in eating habits, but there is no approved drug treatment programme The findings of the study could provide new therapeutic targets, as well as new treatment options The results were published in the latest issue of the journal Hepatology Communications "An increase in the proportion of obese people leads to an increased risk of liver disease in adults and in children," says Dr Kohli "However, only a small percentage of these people develop severe symptoms, such as non-alcoholic fatty liver disease, or NASH." NASH is a liver disease characterized by inflammation and damage to the liver caused by increased fat Although the cause of the disease is still being studied, patients with the disease are accompanied by type 2 diabetes, high cholesterol and other metabolic abnormalities The researchers tested the effects of diet on liver inflammation and the risk of subsequent diseases through a series of trials Since previous studies have found that immune cells are involved in the inflammatory response of adipose tissue in insulin-tolerant patients, the authors hope to detect the role of NKT cells and CD8 T cells in the onset of the disease (BioValleyBioon.com) Bio Valley For More Great Counts! Stay tuned!